Clearmind Medicine (NASDAQ:CMND) Major Shareholder Financial Lp Hrt Sells 3,183 Shares

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 3,183 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $3.32, for a total transaction of $10,567.56. Following the transaction, the insider directly owned 103,492 shares of the company’s stock, valued at $343,593.44. This represents a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total transaction of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total transaction of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt purchased 2,159,052 shares of Clearmind Medicine stock. The shares were purchased at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Stock Performance

NASDAQ CMND remained flat at $3.14 during trading hours on Wednesday. 120,986 shares of the company traded hands, compared to its average volume of 1,140,760. The company has a market cap of $3.20 million, a P/E ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a 52-week low of $2.10 and a 52-week high of $524.00. The stock has a 50-day moving average of $5.92 and a 200-day moving average of $15.64.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings results on Monday, June 15th. The company reported ($6.78) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.